Aim: Omega-3 fatty acid ethyl ester supplements, available by prescription, are common in the treatment of dyslipidaemia in humans. Recent studies show that 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), a metabolite formed from fish oil supplementation, was able to prevent and reverse high fat diet (HFD)-induced fatty liver in mice. In the present study, we investigated the underlying molecular mechanisms responsible for CMPF's hepatic lipid-lowering effects.
contrast, the hepatocellular injury that is associated with the NASH stage of NAFLD, which includes inflammation, liver cell damage, fibrosis and scarring, puts an individual at high risk of developing liver cirrhosis and eventual liver failure. 3 Importantly, the presence of NAFLD contributes to the development of hepatic insulin resistance, leading to impaired glucose homeostasis and, ultimately, promoting the pathogenesis of type 2 diabetes (T2D). 4, 5 At this time, there are no official treatments designed specifically to reduce hepatic fat accumulation, 6, 7 apart from the emerging use of fish oil supplementation. Fish oils are often prescribed to reduce hyperlipidaemia, a condition often seen in obese individuals. 8 In a very recent study, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) was shown to be a major metabolic byproduct resulting from the consumption of Lovaza, (GlaxoSmithKline,
Research Triangle Park, NC, U.S.A) a fish oil (FO) supplementation available by prescription. 9 Despite its previously reported negative effects on pancreatic beta cell function, 10, 11 CMPF was found to reverse and prevent high fat diet (HFD)-induced hepatic steatosis in mouse models. 9 This observation is in line with the reported beneficial effects of Lovaza on regulation of lipid profiles in humans, 12, 13 suggesting that CMPF may be an active component of FO, contributing to the beneficial metabolic effects seen in humans. Interestingly, human studies have also revealed a strong correlation between elevated circulating CMPF and reduced plasma TG levels, associating CMPF with a role in regulating glycolipid metabolism. [14] [15] [16] Mechanistically, CMPF was found to be an inhibitor of acetyl-coA carboxylase (ACC), the master regulator of fatty acid metabolism, as well as having the ability to induce the production of fibroblast growth factor 21 (FGF21). 9 CMPF's long-term preventive effect on HFDinduced hepatic lipid accumulation is absent in FGF21KO mice, suggesting that the long-term beneficial effect of CMPF on metabolism is FGF21 dependent. 9 Whether this observed hepatic lipid-lowering effect is the result of CMPF's direct action on hepatocytes or a result of its indirect effects conveyed through other metabolically responsive tissues remains to be determined. In addition, acute CMPF treatment (2 weeks treatment via i.p. injection) reduced intrahepatic lipid accumulation in diet-induced obese (DIO) and ob/ob mouse models without an elevation in circulating FGF21, suggesting that additional intrahepatic mechanisms exist and are yet to be identified. 9 In the present study we investigated the underlying molecular mechanisms that are responsible for CMPF's intrahepatic lipid-lowering effects and its ability to prevent NAFLD-associated fatty liver development by employing both in vitro and in vivo mouse models.
| MATERIALS AND METHODS

| Animal study design
All animal procedures were approved by the Animal Care Committee at the University of Toronto and were undertaken according to guidelines of the Canadian Council of Animal Care. Male CD1 mice (7 weeks) were utilized for all in vivo studies (Charles River USA). Male C57BL/6 mice (7-9 weeks) were utilized for all in vitro studies (Jackson Laboratories USA). For the chronic model, mice received intraperitoneal injections of sterile saline containing either vehicle (70% ethanol) or CMPF at a concentration of 6 mg/kg for 7 days, while a standard CHOW diet was maintained. Following the final injection, mice received either a diet with 60% kcal from fat or a sucrose-matched control diet for an additional 5 weeks. Further details concerning the diet are provided in Appendix S1.
| In vivo and in vitro assessments
We evaluated body weight and blood parameters and we performed three metabolic tests, glucose, insulin and lipid tolerance. MRI was performed to examine body fat distribution. Liver lipid content and protein expression were also quantified. The direct effects of CMPF on hepatocyte function in vitro was conducted to measure fatty acid uptake and oxidation, lipogenesis, glucose uptake, gluconeogenesis, and FGF21 expression and secretion. More information concerning detailed methods can be found in Appendix S1.
| Microarray
Total RNA from isolated murine livers was processed for microarray analysis at the Princess Margaret Genomics Centre, Toronto, Canada (www.pmgenomics.ca). The R/Bioconductor (www.R-project.org) packages oligo and limma were used for data normalization, quality assessment and statistical analysis. 17, 18 Gene set enrichment analysis (GSEA) using the Mouse Go Pathways, annotated by the Bader Lab (http://download.baderlab.org/EM_Genesets/current_release/Mouse/ symbol/; November 1, 2017 release), was applied for pathway enrichment analysis. 19 All GO sets with 10-1000 members were analysed.
The recommended number of permutations (1000) was performed using the less stringent (gene set) permutation type. GO sets with a P value less than 0.05 and an FDR Q value cut-off of 0.25 were reported as significant. Pathway enrichments were visualized with cytosape, using the enrichment map 19 to visualize networks with a P value cut-off of 0.05, a corrected false discovery rate (FDR) q value cut-off of 25% and an overlap coefficient of 0.5.
| Statistical analysis
Statistical significance was assessed by Student's t-test or two-way ANOVA for repeated measures, followed by Bonferroni analysis when applicable. For all assessments, P < 0.05 was considered significant.
Unless otherwise stated, all data are expressed as MEAN AE SEM. Figure 1D ) and fasting insulin levels ( Figure 1E ). Importantly, this inhibition of HFD-induced weight gain corresponded to significant prevention of HFD-induced insulin resistance, causing insulin sensitivity to remain at a level that was comparable to that with a diet of Con-CHOW ( Figure 1F ). Interestingly, this prevention of HFD-induced insulin resistance did not translate into improved glucose homeostasis ( Figure 1G ). This finding could be a result of CMPF's negative effect on beta cell function as previously reported, in which acute CMPF administration lead to reduced insulin biosynthesis and secretion. 10, 11 Indeed, even at 5 weeks post exposure to CMPF, this impairment of beta cell function remained, shown here through significant downregulation of glucose-stimulated insulin secretion during high-glucose incubation ( Figure 1H ) within islets isolated from CMPF-HFD mice, with no change in total insulin ( Figure 1I ). . Quantification of liver G, triglycerides (n = 13-16) and H) total cholesterol (3) (4) (5) . I, Serum lipid profile following overnight fast (n = 5-6). J, Circulating levels of AST and ALT (n = 5-6). *P < 0.05, **P < 0.01, ***P < 0.001, ****P, 0.0001. All error bars, SEM
| Pre-exposure with CMPF prevents HFD-driven lipid deposition in the liver and adipose tissue in vivo
To investigate the reduced weight gain in mice exposed to CMPF prior to HFD feeding, we first utilized magnetic resonance imaging (MRI) to evaluate body fat distribution. A significantly smaller percentage of both subcutaneous and visceral fat mass over total body mass was observed in CMPF-HFD mice when compared to Con-HFD mice ( Figure 2A and Figure S1A ). Importantly, the percentage of subcutaneous fat mass within CMPF-HFD mice was similar to that of Con-CHOW mice ( Figure 2A ). These observations corresponded to a significantly smaller adipocyte size within the subcutaneous fat of CMPF-HFD mice compared to that of Con-HFD ( Figure 2B and C).
Assessment of gross liver morphology, in combination with Oil Red O staining (Sigma-Aldrich, Ontario, Canada), revealed a reduction in hepatic lipid storage ( Figure 2D ). In addition, the livers of CMPF-HFD mice had a significantly reduced lipid droplet area, with a higher number of medium-to-small sized lipid droplets rather than the primarily large lipid droplets observed in the livers of Con-HFD mice ( Figure 2E and F). Hepatic TG and cholesterol quantification revealed that mice that had received CMPF pre-treatment prior to dietary challenge maintained hepatic lipid content at a level similar to that of Con-CHOW mice ( Figure 2G CMPF at a concentration comparable to that of the in vivo injection.
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CMPF did not directly alter hepatic fatty acid uptake ( Figure 5B ).
However, similar to the increase in fatty acid oxidation previously observed within the islets, 10 CMPF treatment significantly increased hepatic fatty acid oxidation ( Figure 5C ). Unexpectedly, despite CMPF's ability to act as an allosteric inhibitor of ACC1, 9 in vitro CMPF treatment also significantly increased hepatic lipogenesis ( Figure 5D ).
As our measurement of hepatic lipogenesis cannot determine whether the de novo generated lipids originated from TG or cholesterol biosynthesis, we specifically measured the concentration of hepatic cholesterol. Indeed, following acute CMPF treatment, we observed an increase in cholesterol production, shown through an elevation in intracellular and secreted cholesterol content ( Figure 5E and F). This parallels our observations in which CMPF up-regulates protein expression of the major transcription factor (SREBP2) and rate-limiting enzyme (HMGCR) involved in cholesterol biosynthesis (Figure 4 ).
Importantly, we observed an opposite regulation on cholesterol biosynthesis between CMPF (promote) and TOFA (inhibit), the general pharmacological ACC inhibitor; therefore, we suggest that CMPF upregulates cholesterol biosynthesis independently of its previously reported allosteric ACC1 inhibitory properties. 9 As a net result of CMPF's impact on hepatic lipid metabolism, and consistent with our results in vivo ( Figure 1F and Figure 4 ), CMPF treatment corrected lipid-induced insulin resistance, shown here as a significant enhancement of (fat-load impaired) insulin-stimulated AKT phosphorylation relative to fat-supplemented controls ( Figure 5G ). In addition, CMPF treatment did not directly alter hepatic glucose uptake or production ( Figure 5H and I) , nor glycogen content determined via PAS staining in CMPF-HFD mice ( Figure 1E) , suggesting that the effect of CMPF within the liver occurs primarily through the regulation of lipid metabolism.
| CMPF increases FGF21 expression and secretion from primary hepatocytes via ACC inhibition in vitro
We also investigated the cellular mechanism behind CMPF's ability to drive hepatic FGF21 production. 9 Within isolated hepatocytes, treatment with CMPF increased both the expression ( Figure 5K ) and secretion of FGF21 ( Figure 5I ). The expression of FGF21 can be initiated through activation of the transcription factor PPARα. 22 
| DISCUSSION
CMPF is an active metabolite of FO and is independent of its mother compound (FO); both demonstrate protective effects on hepatic lipid metabolism. In the present study, we utilized both in vivo and in vitro models and undertook detailed mechanistic lipid research to gain an understanding of how CMPF protects against the development of fatty liver.
Close examination of lipid accumulation within CMPF-HFDtreated livers revealed a greater number of small-sized lipid droplets, opposed to the large-sized droplets more characteristic of liver steatosis. 28 These data suggest that the lipid accumulation occurring within the liver as a result of high-fat diet feeding is significantly reduced following transient CMPF treatment. However, the presence of small lipid droplets suggests that excessive absorption of free fatty acids would further contribute to CMPF's prolonged protective effect against HFD-induced hepatic steatosis, thus maintaining hepatic insulin sensitivity. 29, 30 Although CMPF prevented diet-enriched genes in promoting hepatic lipid storage, microarray data shows no significant changes in genes of enzymes that are involved in the regulation of hepatic lipid production, which includes glycerol-3-phosphate acyltransferase (GPAT), phosphatidate phosphatase (PAP) and diglyceride acyltransferase (DGAT). Further studies focusing on CMPF's effect on the activity of enzymes involved in hepatic lipid production are required. We believe that enrichment of genes in the lipid biosynthesis pathway are a consequence of CMPF's defense against HFD stress, resulting from early activation of the ACC inhibtion-FGF21 production-Beta oxidation loop. In addition, the prolonged effect of CMPF could potentially be the result of epigenetic changes, leading to alteration in long-term gene expression, that are yet to be determined.
Fatty liver is usually associated with elevated levels of ALT and AST, but it is surprising to observe no change in ALT, while AST levels are increased. However, studies suggest that ALT levels can fluctuate;
therefore, measurement at a single time point is insufficient to reach conclusions concerning the normalcy of ALT. 31 In our studies, we consistently found that there is no change in circulating TG levels despite a reduction in hepatic TG in the various diet-induced dyslipidaemic models upon CMPF treatment. We believe our study model (1 week of CMPF prior to 5 weeks of an HFD) is limited in its ability to determine only the preventive effects of CMPF on the early stages of NAFLD, the fatty liver stage, as the more advanced pathological characteristics of NAFLD, which include inflammation and fibrosis, begin to appear only after at least 18 weeks of a HFD intervention. 32 Additionally, male C57BL/6 mice were treated with CMPF for 1 week prior to a 3-week period of a low-methionine, choline-deficient diet (MCD), which is the most widely used diet to induce NAFLD/NASH. We found no significant differences in liver TG content ( Figure S1H ) and serum TG levels ( Figure S1I ), suggesting that CMPF treatment cannot prevent severe liver damage and progressive fibrosis ( Figure S1H ). Therefore, we believe that CMPF's effect on regulation of hepatic lipid metabolism can only prevent and treat early stages of NAFLD, the fatty liver stage, and the effect of CMPF on lowering hepatic TG cannot be translated into an effect on circulating TG.
Our study revealed that CMPF can accumulate in liver tissue but not in adipose tissue; thus, we propose that OAT2 facilitates CMPF's entry into the hepatocyte and exerts its direct effect. Because of the absence of OATs expression, we believe adipose tissue is unlikely to be the primary target tissue for CMPF. Studies have shown that OAT2 is capable of transporting a wide range of substrates including dicarboxylates such as CMPF, 33, 34 and it is significantly expressed within both whole liver and isolated hepatocytes. Once CMPF has entered the hepatocyte, it enhances fatty acid oxidation via its inhibitory effect on ACC 35 and directly induces FGF21 production, all of which could contribute to the improvement observed in the acute lipid tolerance test ( Figure 5A ). However, CMPF might have an effect on fat absorption, chylomicron release or lipid particle clearance that would affect the lipid turnover rate, which requires further investigation.
We also observed, paradoxically, an increase in lipid production in isolated hepatocytes. Further analysis suggests that an increase in cholesterol biosynthesis upon CMPF treatment may account, in part, for the unexpected increase in lipid production. This increase in hepatic cholesterol production aligned with the significant increase observed in hepatic cholesterol secretion. In particular, high-density lipoprotein (HDL) could bring excess cholesterol back to the liver via reverse cholesterol transport for elimination. 36 Indeed, we observed a significant increase in circulating HDL particles in ob/b mice treated acutely with CMPF (data not shown). Although the exact mechanism leading to this increase in cholesterol production remains unclear, we know that it occurs independently of CMPF's inhibitory effect on ACC1, as 5-tetradecyloxy-2-furoic acid (TOFA), the general pharmacological ACC inhibitor, induces an opposite effect on the regulation of cholesterol biosynthesis from CMPF. Further studies to elucidate the underlying mechanism responsible for CMPF-increased cholesterol production are warranted.
SREBP-1c is the key lipogenic transcription factor responsible for transcription of the genes involved in fatty acid synthesis. 37, 38 The hepatic insulin resistance that is associated with diet-induced NAFLD is probably the major driving force behind the increased expression and activity of SREBP-1c, as suggested by many studies. 39, 40 It is intriguing to see that the expression/activity of SREBP1c is maintained at the same level as that observed in CHOW-fed mice, even . I, FGF21 secretion into hepatic media following treatment with CMPF, TOFA (100 μM), S-2E (10 μM) and PF-05175157 (10 μM) and AICAR in isolated hepatocytes. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. All error bars, SEM preventive effect of CMPF on diet-induced enlargement of adipocytes probably occurs as a prolonged metabolic consequence of CMPF's maintenance of hepatic insulin sensitivity and elevation in circulating FGF21.
Despite the observed beneficial effects of CMPF on regulating hepatic lipid homeostasis and insulin sensitivity, it cannot be ignored that they occur in combination with the negative effects of CMPF on beta cells. 10, 11 In conclusion, the results of our study provide further insight into the hepatic mechanism behind CMPF's beneficial effect in preventing diet-induced fatty liver. CMPF increases hepatic fatty acid oxidation in parallel with an increase in hepatic FGF21 production and secretion via its inhibitory effect on ACC. In return, FGF21 can further enhance hepatic fatty acid oxidation via its autocrine or endocrine action. This feed-back loop that is established among fatty acid oxidation, ACC inhibition, and FGF21 production during CMPF exposure, primes the liver with a prolonged effect that prevents hepatic lipid synthesis and storage via negative regulation of the Insig2/SREBP-1c/FAS axis.
Simultaneously, it promotes lipid utilization to fight against dietinduced hepatic lipid accumulation and to maintain the insulin sensitivity that remains even 5 weeks after CMPF treatment. 
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